日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414

关于在未接受过生物制剂DMARD治疗的活动性银屑病关节炎患者中应用Bimekizumab治疗的更正:来自III期随机、安慰剂对照、活性参考BE OPTIMAL研究的52周疗效和安全性结果 Ann Rheum Dis. 2023;82:1404-1414

Ritchlin, Christopher T; Coates, Laura C; McInnes, Iain B; Mease, Philip J; Merola, Joseph F; Tanaka, Yoshiya; Asahina, Akihiko; Gossec, Laure; Gottlieb, Alice B; Warren, Richard B; Ink, Barbara; Bajracharya, Rajan; Shende, Vishvesh; Coarse, Jason; Landewé, Robert B M

Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years

接受司库奇尤单抗治疗 2 年的银屑病关节炎患者的放射学进展状态与低疾病活动度之间的关系

Mease, Philip J; Coates, Laura C; Gaillez, Corine; Shew, Alexis; Bao, Weibin; Ritchlin, Christopher T

The Function of Efhd1 (+) Telocytes in the Synovial Lymphatic System and Inflammatory-Erosive Arthritis.

Efhd1 (+) 端粒细胞在滑膜淋巴系统和炎症侵蚀性关节炎中的功能。

Peng Yue, Mark Kenney H, Kobryn Andriy, Lydon Sean, de Mesy Bentley Karen L, Xing Lianping, Korman Benjamin D, Ritchlin Christopher T, Schwarz Edward M

Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials

托法替尼治疗强直性脊柱炎患者的疗效/安全性(按基线体重指数分层):一项 2/3 期试验的事后分析

Norton, Hillary; Sliwinska-Stanczyk, Paula; Hala, Tomas; El-Zorkany, Bassel; Stockert, Lori; Mundayat, Rajiv; Wang, Lisy; Ritchlin, Christopher T

Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

更正:比美珠单抗治疗银屑病关节炎患者的安全性和有效性:两项3期研究的2年结果

Mease, Philip J; Merola, Joseph F; Tanaka, Yoshiya; Gossec, Laure; McInnes, Iain B; Ritchlin, Christopher T; Landewé, Robert B M; Asahina, Akihiko; Ink, Barbara; Heinrichs, Andrea; Bajracharya, Rajan; Shende, Vishvesh; Coarse, Jason; Coates, Laura C

Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

研究总结:比美珠单抗治疗银屑病关节炎患者的安全性和有效性:两项3期研究的2年结果

Mease, Philip J; Merola, Joseph F; Tanaka, Yoshiya; Gossec, Laure; McInnes, Iain B; Ritchlin, Christopher T; Landewé, Robert B M; Asahina, Akihiko; Ink, Barbara; Heinrichs, Andrea; Bajracharya, Rajan; Shende, Vishvesh; Coarse, Jason; Coates, Laura C

Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study

古塞库单抗在未接受过生物制剂治疗且患有严重疾病活动的银屑病关节炎患者中的疗效:一项3期研究的事后分析

Ritchlin, Christopher T; Lubrano, Ennio; Chimenti, Maria Sole; Leibowitz, Evan; Sharaf, Mohamed; Rampakakis, Emmanouil; Nantel, Francois; Lavie, Frederic; Deodhar, Atul

Automated Joint Space Detection Improves Bone Segmentation Accuracy

自动关节间隙检测可提高骨骼分割精度

Kenney, H Mark; Lichau, Daniel; Blanc, Rémi; Schnur, Lindsay; Bell, Richard D; Ritchlin, Christopher T; Schwarz, Edward M; Awad, Hani A; Wood, Ronald W

Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial

Sonelokimab,一种用于治疗活动性银屑病关节炎的IL-17A/IL-17F抑制纳米抗体:一项随机、安慰剂对照的II期试验

McInnes, Iain B; Coates, Laura C; Mease, Philip J; Ogdie, Alexis; Kavanaugh, Arthur; Eder, Lihi; Schett, Georg; Kivitz, Alan; McGonagle, Dennis; Brennan, Nuala; Godwood, Alex; Cullen, Eva; Reich, Kristian; Ritchlin, Christopher T; Merola, Joseph F

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

IL-23 的过去、现在和未来:推进 IL-23 科学和治疗的路线图

Krueger, James G; Eyerich, Kilian; Kuchroo, Vijay K; Ritchlin, Christopher T; Abreu, Maria T; Elloso, M Merle; Fourie, Anne; Fakharzadeh, Steven; Sherlock, Jonathan P; Yang, Ya-Wen; Cua, Daniel J; McInnes, Iain B